News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
Top 10 Biopharma M&A Deals of 2025: Market Analysis
This article analyzes the top 10 biopharma M&A deals of 2025, highlighting their significance for the market. Key insights for BD teams, investors, and analysts are provided.
FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC
The FDA has approved Atezolizumab as an adjuvant treatment for patients with ctDNA MRD-positive muscle-invasive bladder cancer (MIBC), marking a significant advancement in oncology. This approval is expected to influence investment strategies and competitive dynamics in the pharmaceutical sector.
Layoff Tracker: Takeda and Novartis Restructuring Impact
Takeda announces significant layoffs affecting 4,500 employees, while Novartis reduces its biomedical research staff. This article explores the implications for the pharmaceutical industry.
Daré Bioscience Launches Phase 2 Study for DARE-HPV Treatment
Daré Bioscience has initiated a Phase 2 study for DARE-HPV, a novel treatment for persistent high-risk HPV infection, addressing a significant gap in available therapies.
Layoff Tracker: Takeda and Novartis Restructure Amid Industry Changes
Takeda announces significant layoffs affecting 4,500 employees, while Novartis cuts biomedical research staff. This article explores the implications for the pharmaceutical industry.
M&A in Pharmaceuticals: Bigger, Bolder, and Far More Strategic
This article delves into the recent trends in pharmaceutical mergers and acquisitions, highlighting strategic implications for investors and BD teams.
New FDA Approach to Drug Prices: Implications for Drug Approvals
The FDA's recent shift in drug pricing strategy introduces uncertainty in the drug approval process, raising questions for pharmaceutical stakeholders.
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer
The FDA has approved Atezolizumab for muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options. This approval has important implications for investors and pharmaceutical teams.
UCB Acquires Antibody Treatment Maker: Implications for Autoimmune Disease Market
UCB's recent acquisition of a company specializing in antibody treatments for autoimmune diseases could reshape the competitive landscape. This article explores the implications for investors and pharma teams.
Big Pharma M&A Set for Mega Year Amid Patent Expiries
As patent expiries loom, Big Pharma is gearing up for a significant year of mergers and acquisitions, reshaping the competitive landscape.
Citius Pharmaceuticals Stock Update: Cancer and Anti-Infective Pipeline Insights
Citius Pharmaceuticals is making strides in its cancer and anti-infective pipeline. This article explores the latest clinical trial results and their implications for investors.
Regulatory Round-Up: Key FDA Approvals for Cancer Drugs
This article reviews the recent FDA approvals for cancer drugs, highlighting key developments and their impacts on the pharmaceutical landscape.
10 Clinical Trials to Watch in the First Half of 2026
This article highlights the most significant clinical trials to monitor in the first half of 2026, offering insights for investors and pharma teams.
Pharma M&A Round-Up: April 2026 Insights and Analysis
This article provides a comprehensive analysis of the recent M&A activities in the pharmaceutical sector for April 2026, highlighting key insights for business development teams and investors.
FDA Leadership Changes Crisis: Implications for Drug Approvals
The FDA faces a leadership crisis with three key exits in 2026, raising concerns about drug approval processes and industry stability.
Bio-IT World Conference 2026: Key Insights and Highlights
The Bio-IT World Conference 2026 in Boston showcased groundbreaking innovations in bioinformatics. Here are the key takeaways and insights from the event.
FDA Approvals: Key Cancer Drug Updates for May 2026
This article reviews significant FDA approvals for cancer drugs in May 2026, highlighting their implications for the pharmaceutical landscape.
Makary Resigns as FDA Commissioner: Implications for Drug Approvals
Dr. Robert Makary's resignation as FDA Commissioner raises significant questions about future drug approvals and regulatory strategies. This article explores the implications for the pharmaceutical industry.
Amgen Inc Stock: Lung Cancer Setback Meets Steady Cash Flow
Amgen Inc faces a setback in lung cancer trials but maintains strong cash flow. This article explores its implications for investors and pharma teams.
Four FDA Actions Reshaping Drug Development in 2026
This article discusses four significant FDA actions that are set to reshape drug development in 2026, highlighting their implications for the pharmaceutical industry.